Compare First Trust Cloud Computing ETF (SKYY) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust Cloud Computing ETF vs State Street SPDR S&P Biotech ETF — how do they compare? First Trust Cloud Computing ETF trades at $174.2 (market cap $3.47B), while State Street SPDR S&P Biotech ETF trades at $154 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 2.9× First Trust Cloud Computing ETF's market cap, and First Trust Cloud Computing ETF is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold First Trust Cloud Computing ETF for 85 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| SKYY | XBI | |
|---|---|---|
Market Cap | $3.47B | $10.11B |
Volume | 176,159 | 12,903,266 |
52-Week High | $171.01 | $169.55 |
52-Week Low | $104.16 | $104.99 |
Typical Hold Time | 85 Days | 38 Days |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Trust Cloud Computing ETF (SKYY) trades at $174.09, up 1.94% with bullish technical signals from moving averages. The ETF recently hit a new 52-week high, reflecting strong momentum in cloud computing stocks driven by AI infrastructure demand. Technical indicators show support at $169 and resistance at $171-173, with the current price near recent highs.
SKYY offers diversified exposure to cloud infrastructure and software companies benefiting from secular trends in AI adoption and digital transformation. Key risks include sector concentration and market volatility, while institutional sentiment remains positive given the long-term growth prospects in cloud computing.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
